Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.

Overview

authors

Spiera, Robert F
Jinich, Sarah
Jannat-Khah, Deanna

publication date

May 11, 2021

published in

Annals of the rheumatic diseases Journal

Research

keywords

Antirheumatic Agents
COVID-19
COVID-19 Vaccines
Immunogenicity, Vaccine
Rituximab

Identity

Scopus Document Identifier

85105984320

Digital Object Identifier (DOI)

10.1136/annrheumdis-2021-220604

PubMed ID

33975857

Additional Document Info

has global citation frequency

76

volume

80

issue

10